
Evaluating Efficacy of Second-Line RCC Treatments Post-Immunotherapy
Second-line therapy for renal cell carcinoma (RCC) offers multiple options after progression on frontline immunotherapy plus tyrosine kinase inhibition (TKI). A virtual Case-Based Roundtable event discussing a patient with clear cell RCC was moderated by …